stoxline Quote Chart Rank Option Currency Glossary
Heron Therapeutics, Inc. (HRTX)
1.41  -0.03 (-2.08%)    12-07 16:00
Open: 1.43
High: 1.47
Volume: 1,340,006
Pre. Close: 1.44
Low: 1.36
Market Cap: 212(M)
Technical analysis
2023-12-07 4:21:12 PM
Short term     
Mid term     
Targets 6-month :  1.83 1-year :  2.14
Resists First :  1.57 Second :  1.83
Pivot price 1.3
Supports First :  0.9 Second :  0.5
MAs MA(5) :  1.42 MA(20) :  1.13
MA(100) :  1.19 MA(250) :  1.74
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  84 D(3) :  88.8
RSI RSI(14): 64.9
52-week High :  3.41 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HRTX ] has closed below upper band by 31.4%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.47 - 1.48 1.48 - 1.49
Low: 1.34 - 1.35 1.35 - 1.36
Close: 1.4 - 1.41 1.41 - 1.42
Company Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Headline News

Mon, 04 Dec 2023
Should You Buy Heron Therapeutics Inc (HRTX) Stock on Monday? - InvestorsObserver

Thu, 30 Nov 2023
Why Heron Therapeutics Stock Is A Compelling Buy Into 2024 (NASDAQ:HRTX) - Seeking Alpha

Tue, 28 Nov 2023
Should You Add Heron Therapeutics Inc (HRTX) Stock to Your Portfolio Tuesday? - InvestorsObserver

Mon, 27 Nov 2023
Is Heron Therapeutics Inc (HRTX) a Good Buy in the Biotechnology Industry? - InvestorsObserver

Wed, 15 Nov 2023
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript - Yahoo Finance

Tue, 14 Nov 2023
Heron Therapeutics: Q3 Earnings Snapshot - Houston Chronicle

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 150 (M)
Shares Float 114 (M)
Held by Insiders 0.7 (%)
Held by Institutions 92 (%)
Shares Short 17,590 (K)
Shares Short P.Month 19,360 (K)
Stock Financials
EPS -0.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.21
Profit Margin -97.5 %
Operating Margin -66.3 %
Return on Assets (ttm) -24.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 18.3 %
Gross Profit (p.s.) -0.34
Sales Per Share 0.81
EBITDA (p.s.) -0.64
Qtrly Earnings Growth 0 %
Operating Cash Flow -99 (M)
Levered Free Cash Flow -51 (M)
Stock Valuations
PE Ratio -1.61
PEG Ratio -0.1
Price to Book value -7.05
Price to Sales 1.72
Price to Cash Flow -2.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android